NCT02436564|Unknown
In Vitro Models of Liver and Pancreatic Cancer
A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies
Loading search results
A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies
Sponsor study identifier
observational
75
1 country
1
Study Start
July 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
Not reported
Date not reportedThe primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies. Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 30, 2015
Actual (reported)May 7, 2015
Actual (reported)July 2015
Date type not reportedThis date has not been verified as actual or estimated.
September 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.
3 years
Proportion of tumour-derived organoids that are genetically identical to the source tumour.
3 years
Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients who are undergoing surgical resenctions of liver, biliary or pancreas cancers that are able to give informed consent
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
fresh tissue, frozen tissue
Kourosh Saeb-Parsy, PhD, FRCS
Cambridge Univeristy Hospitals
First Submitted
April 30, 2015
First Posted
May 7, 2015
Study Start
July 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2018
SBRT Pre-operatively for Pancreatic Cancer
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
July 14, 2016
Record last verified: 2016-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: